Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Coherus Oncology's Revenue for the
three
months ended in Mar. 2026 was €10.65 Mil. Coherus Oncology's average Accounts Receivable for the
three
months ended in Mar. 2026 was €17.15 Mil.
Hence, Coherus Oncology's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.62.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Coherus Oncology Receivables Turnover Related Terms
Coherus Oncology Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Coherus Oncology's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8C5 vs NAUT, AVXL, SLNCF: Receivables Turnover Comparison
For the Biotechnology subindustry, Coherus Oncology's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coherus Oncology Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coherus Oncology's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Coherus Oncology's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coherus Oncology (FRA:8C5) has a Receivables Turnover of 0.62 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Coherus Oncology and its competitors. According to the industry distribution chart, Coherus Oncology ranks #712 out of 841 companies in the Biotechnology industry, placing it in the top 84.7%.
Is Coherus Oncology's Receivables Turnover too high?
Coherus Oncology's current Receivables Turnover is 0.62. The Biotechnology industry median Receivables Turnover is 5.27. Coherus Oncology's value of 0.62 is 88.2% below this industry median. Based on the distribution chart, Coherus Oncology ranks #712 out of 841 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Coherus Oncology has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Coherus Oncology's Receivables Turnover compare to NAUT and AVXL?
According to the Biotechnology industry distribution chart, Coherus Oncology ranks #712 out of 841 companies for Receivables Turnover. This places Coherus Oncology in the lower half of its industry. The industry median Receivables Turnover is 5.27. Coherus Oncology's value of 0.62 is 88.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coherus Oncology's current Receivables Turnover of 0.62 is 88.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Coherus Oncology and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coherus Oncology's current Receivables Turnover is 0.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coherus Oncology stock overvalued right now?
Based on GuruFocus' analysis, Coherus Oncology (FRA:8C5) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.65, compared to a current price of €1.24 — trading 90.3% above its estimated fair value. The current Receivables Turnover is 0.62 and 88.2% below the Biotechnology industry median of 5.27. Coherus Oncology's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Coherus Oncology (FRA:8C5), the current Receivables Turnover is 0.62 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coherus Oncology (FRA:8C5) Overvalued in 2026?
Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued.
The current stock price of €1.24 is trading 90.3% above its estimated GF Value™ of €0.65.
GuruFocus considers Coherus Oncology to be Significantly Overvalued.
Key valuation signals for FRA:8C5:
Receivables Turnover: 0.62
GF Value™: €0.65 vs. price of €1.24 (90.3% above fair value)
Industry Position: 88.2% below the Biotechnology median (#712 of 841)
No single metric tells the full story. See the FRA:8C5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
49GF Score
Get the complete analysis for FRA:8C5
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8C5 has been successfully added to your 
